# Provider Summary — Tissue repair & energy support draft

_Provider-facing clinical summary. Source-attributed. Not patient-facing._

- **Patient:** DEMO-001
- **Provider:** dr_demo
- **Plan status:** signed_off
- **Assessment date:** —
- **Signed off:** 2026-06-14T00:33:03.739+00:00

## Clinical context (snapshot)
- Primary phenotype: babesia_pattern
- Secondary phenotype: neuroinflammation
- Recovery stage: improving
- Safety: High Review Priority — critical 0, high 3
- Outcomes: clinical improvement 69, functional 68

## Components (1)

### 1. BPC-157 (peptide)
- Rationale: Tissue repair / gut-lining support.
- Provider instruction: As directed by your provider each morning.
- Monitoring: Note any injection-site reactions.
- Safety: Stop and contact the clinic if you feel unwell.
- Dosing reference (NOT provider-reviewed): Reference dosing as documented in source (verbatim; not a recommendation).
  - Source: Internal Clinic Protocols — Provider (internal_protocol)

_Provider-only. Generated from the signed-off plan; original sources remain the source of truth._